These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15867163)

  • 21. Fibrinolytic agents and their effects on the haemostatic system.
    Kluft C
    Klin Wochenschr; 1988; 66 Suppl 12():50-4. PubMed ID: 2964542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of ultrasound on thrombolysis of middle cerebral artery occlusion.
    Eggers J; Koch B; Meyer K; König I; Seidel G
    Ann Neurol; 2003 Jun; 53(6):797-800. PubMed ID: 12783427
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impaired resolution of massive pulmonary embolism associated with an inhibited fibrinolytic response.
    Deitcher SR; Lucore CL; Eisenberg PR
    Am J Med; 1994 May; 96(5):483-4. PubMed ID: 8192182
    [No Abstract]   [Full Text] [Related]  

  • 24. Ultrasound enhanced thrombolysis in acute arterial ischemia.
    Tsivgoulis G; Culp WC; Alexandrov AV
    Ultrasonics; 2008 Aug; 48(4):303-11. PubMed ID: 18511094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An ideal thrombolytic and antithrombotic agent?
    Matsuo O
    J Thromb Haemost; 2005 Oct; 3(10):2154-5. PubMed ID: 16194193
    [No Abstract]   [Full Text] [Related]  

  • 26. Fibrinolytic profiles in local low-dose thrombolysis with streptokinase and recombinant tissue plasminogen activator.
    Berridge DC; Earnshaw JJ; Westby JC; Makin GS; Hopkinson BR
    Thromb Haemost; 1989 Apr; 61(2):275-8. PubMed ID: 2501898
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro sonothrombolysis with duplex ultrasound: first results using a simplified model.
    Holscher T; Raman R; Ernström K; Parrish J; Le DT; Lyden PD; Mattrey RF
    Cerebrovasc Dis; 2009; 28(4):365-70. PubMed ID: 19641311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke.
    Alexandrov AV; Molina CA; Grotta JC; Garami Z; Ford SR; Alvarez-Sabin J; Montaner J; Saqqur M; Demchuk AM; Moyé LA; Hill MD; Wojner AW;
    N Engl J Med; 2004 Nov; 351(21):2170-8. PubMed ID: 15548777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Report of tissue plasminogen activator (tPA) injection in a very low dose for the treatment of posttrabeculectomy fibrin.
    Burnstein Y; Higginbotham EJ
    J Glaucoma; 1998 Oct; 7(5):361. PubMed ID: 9786567
    [No Abstract]   [Full Text] [Related]  

  • 30. The search for the ideal thrombolytic agent.
    Verstraete M
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):4B-10B. PubMed ID: 2959714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit.
    Marder VJ; Landskroner K; Novokhatny V; Zimmerman TP; Kong M; Kanouse JJ; Jesmok G
    Thromb Haemost; 2001 Sep; 86(3):739-45. PubMed ID: 11583303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific determination and identification of cross-linked fibrin degradation products in patients under thrombolytic therapy for myocardial infarction.
    Soria J; Soria C; Mirshahi M; Xi M; Mirshahi M; Samama MM; Caen JP
    Semin Thromb Hemost; 1987 Apr; 13(2):223-7. PubMed ID: 3114888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
    Bachmann F
    Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
    Eisenberg PR; Jaffe AS; Stump DC; Collen D; Bovill EG
    Circulation; 1990 Oct; 82(4):1159-68. PubMed ID: 2119264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fibrinogen-mimicking, multiarm nanovesicles for human thrombus-specific delivery of tissue plasminogen activator and targeted thrombolytic therapy.
    Huang Y; Gu B; Salles-Crawley II; Taylor KA; Yu L; Ren J; Liu X; Emerson M; Longstaff C; Hughes AD; Thom SA; Xu XY; Chen R
    Sci Adv; 2021 Jun; 7(23):. PubMed ID: 34078604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Letter by Gaberel et Al regarding article, "dose effect of intraventricular fibrinolysis in ventricular hemorrhage".
    Gaberel T; Emery E; Vivien D
    Stroke; 2011 Sep; 42(9):e548-9; author reply e550. PubMed ID: 21817144
    [No Abstract]   [Full Text] [Related]  

  • 37. Predicting rtPA associated ICH in acute stroke.
    Bruno A
    Stroke; 2004 Dec; 35(12):2762; author reply 2762-3. PubMed ID: 15514198
    [No Abstract]   [Full Text] [Related]  

  • 38. Evolution of plasma specific fibrin degradation products during thrombolytic therapy in patients with thrombo-embolism.
    Faivre R; Mirshahi M; Ducellier D; Soria C; Soria J; Mirshahi M; Kieffer Y; Bassand JP; Caen J; Maurat JP
    Thromb Res; 1988 May; 50(4):583-9. PubMed ID: 3413720
    [No Abstract]   [Full Text] [Related]  

  • 39. Novel and emerging therapies: thrombus-targeted fibrinolysis.
    Lippi G; Mattiuzzi C; Favaloro EJ
    Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
    Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
    Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.